Additionally, neutralizing antibodies against CCL2 (anti-human CNTO888 and anti-mouse C1142) in combination with docetaxel diminish prostate cancer cell–mediated tumor burden and induce tumor regression [51]. This evidence concerns the gene CCL2 and prostate carcinoma.